Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Kotenko, Sergei V
and
Pestka, Sidney
2000.
Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes.
Oncogene,
Vol. 19,
Issue. 21,
p.
2557.
Han, Chun-Sheng
Chen, Yizhen
Ezashi, Toshihiko
and
Roberts, R. Michael
2001.
Antiviral activities of the soluble extracellular domains of type I interferon receptors.
Proceedings of the National Academy of Sciences,
Vol. 98,
Issue. 11,
p.
6138.
da Silva, Antonio J.
Brickelmaier, Margot
Majeau, Gerard R.
Lukashin, Alexander V.
Peyman, John
Whitty, Adrian
and
Hochman, Paula S.
2002.
Comparison of Gene Expression Patterns Induced by Treatment of Human Umbilical Vein Endothelial Cells with IFN-α2b vs. IFN-β1a: Understanding the Functional Relationship Between Distinct Type I Interferons That Act Through a Common Receptor.
Journal of Interferon & Cytokine Research,
Vol. 22,
Issue. 2,
p.
173.
Whitty, Adrian
and
Karpusas, Michael
2003.
Protein Structure.
p.
483.
Arduini, Robert M
Li, Zhifang
Rapoza, Alan
Gronke, Robert
Hess, Donna M
Wen, Dingyi
Miatkowski, Konrad
Coots, Caroline
Kaffashan, Azita
Viseux, Nelly
Delaney, Jeannine
Domon, Bruno
Young, Carmen N
Boynton, Raymond
Chen, Ling Ling
Chen, Liqing
Betzenhauser, Matthew
Miller, Stephan
Gill, Alan
Pepinsky, R.Blake
Hochman, Paula S
and
Baker, Darren P
2004.
Expression, purification, and characterization of rat interferon-β, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters.
Protein Expression and Purification,
Vol. 34,
Issue. 2,
p.
229.
Lamken, Peter
Lata, Suman
Gavutis, Martynas
and
Piehler, Jacob
2004.
Ligand-induced Assembling of the Type I Interferon Receptor on Supported Lipid Bilayers.
Journal of Molecular Biology,
Vol. 341,
Issue. 1,
p.
303.
Roisman, Laila C.
Jaitin, Diego A.
Baker, Darren P.
and
Schreiber, Gideon
2005.
Mutational Analysis of the IFNAR1 Binding Site on IFNα2 Reveals the Architecture of a Weak Ligand–Receptor Binding-site.
Journal of Molecular Biology,
Vol. 353,
Issue. 2,
p.
271.
Pachner, Andrew R.
Dail, Donna
Pak, Elena
and
Narayan, Kavitha
2005.
The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies.
Journal of Neuroimmunology,
Vol. 166,
Issue. 1-2,
p.
180.
Lamken, Peter
Gavutis, Martynas
Peters, Imke
Van der Heyden, José
Uzé, Gilles
and
Piehler, Jacob
2005.
Functional Cartography of the Ectodomain of the Type I Interferon Receptor Subunit ifnar1.
Journal of Molecular Biology,
Vol. 350,
Issue. 3,
p.
476.
Brierley, Melissa M.
and
Fish, Eleanor N.
2005.
Stats: Multifaceted Regulators of Transcription.
Journal of Interferon & Cytokine Research,
Vol. 25,
Issue. 12,
p.
733.
Filpula, David
and
Zhao, Hong
2008.
Releasable PEGylation of proteins with customized linkers.
Advanced Drug Delivery Reviews,
Vol. 60,
Issue. 1,
p.
29.
Bobst, Cedric E.
Abzalimov, Rinat R.
Houde, Damian
Kloczewiak, Marek
Mhatre, Rohin
Berkowitz, Steven A.
and
Kaltashov, Igor A.
2008.
Detection and Characterization of Altered Conformations of Protein Pharmaceuticals Using Complementary Mass Spectrometry-Based Approaches.
Analytical Chemistry,
Vol. 80,
Issue. 19,
p.
7473.
Constantinescu, Cris
and
Fahey, Angela
2009.
xPharm: The Comprehensive Pharmacology Reference.
p.
1.
Baker, Darren P.
Pepinsky, Robert Blake
Brickelmaier, Margot
Gronke, Robert S.
Hu, Xiao
Olivier, Kenneth
Lerner, Michaela
Miller, Larisa
Crossman, Mary
Nestorov, Ivan
Subramanyam, Meena
Hitchman, Stacy
Glick, Gabrielle
Richman, Sandra
Liu, Shifang
Zhu, Ying
Panzara, Michael A.
and
Davar, Gudarz
2010.
PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis.
Journal of Interferon & Cytokine Research,
Vol. 30,
Issue. 10,
p.
777.
Kaltashov, Igor A.
Bobst, Cedric E.
Abzalimov, Rinat R.
Berkowitz, Steven A.
and
Houde, Damian
2010.
Conformation and dynamics of biopharmaceuticals: Transition of mass spectrometry-based tools from academe to industry.
Journal of the American Society for Mass Spectrometry,
Vol. 21,
Issue. 3,
p.
323.
Rudick, Richard A.
and
Goelz, Susan E.
2011.
Beta-interferon for multiple sclerosis.
Experimental Cell Research,
Vol. 317,
Issue. 9,
p.
1301.
Atanasova, Mariya
and
Whitty, Adrian
2012.
Understanding cytokine and growth factor receptor activation mechanisms.
Critical Reviews in Biochemistry and Molecular Biology,
Vol. 47,
Issue. 6,
p.
502.
Kondiah, Pierre P.D.
Tomar, Lomas K.
Tyagi, Charu
Choonara, Yahya E.
Modi, Girish
du Toit, Lisa C.
Kumar, Pradeep
and
Pillay, Viness
2013.
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.
International Journal of Pharmaceutics,
Vol. 456,
Issue. 2,
p.
459.
Krause, Christopher D.
Digioia, Gina
Izotova, Lara S.
Xie, Junxia
Kim, Youngsun
Schwartz, Barbara J.
Mirochnitchenko, Olga V.
and
Pestka, Sidney
2013.
Ligand-independent interaction of the type I interferon receptor complex is necessary to observe its biological activity.
Cytokine,
Vol. 64,
Issue. 1,
p.
286.
Samarajiwa, Shamith A.
Mangan, Niamh E.
Hardy, Matthew P.
Najdovska, Meri
Dubach, Daphne
Braniff, Susie-Jane
Owczarek, Catherine M.
and
Hertzog, Paul J.
2014.
Soluble IFN Receptor Potentiates In Vivo Type I IFN Signaling and Exacerbates TLR4-Mediated Septic Shock.
The Journal of Immunology,
Vol. 192,
Issue. 9,
p.
4425.